Register your Account

Sign Up with us and Enjoy!
User name Email First Name Last Name Contact info

A password will be e-mailed to you.

Sequenom Jumps On Upgrade – HK, GFA, GNBT, SQNM, IDIX

NEW YORK, November 14,2012 (MESHPRESS) –, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following Tuesday’s Top Gainers:-

Halcon Resources Corp(NYSE:HK) shares jumped 9.11% to $5.87 in the last trading session after the company reported a third quarter net loss of $20.18 million or $0.11 per share, as compared with a profit of $11.8 million or $0.45 per share. Analysts estimated breakeven per share for the period. Revenue for the period stood at $73.1 million, matching the consensus, compared with $24.2 million a year ago.

 Can HK Continue To Move Higher? Find Out Here

Gafisa SA (ADR)(NYSE:GFA) shares climbed 8.31% to $3.91. JPMorgan Chase upgraded shares of Gafisa from an underweight rating to a neutral rating in a research report sent to investors last month. Separately, analysts at Goldman Sachs downgraded shares of Gafisa SA from a neutral rating to a sell rating in a research note to investors on October 1.

Can GFA Extend Gain? Find Out Here

Generex Biotechnology Corporation(OTC:GNBT) shares gained 7.79% to $0.0415 in the last trading session. The company provided an update on company initiatives. Antigen Express, Inc., a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial were the subject of an end of Phase II study report written for submission to the FDA with input from the Antigen Express AE37 Breast Cancer Vaccine Scientific Advisory Board (SAB) of Internationally-recognized experts in the field of breast cancer.

How Should Investors Trade GNBT Now? Find Out Here

Sequenom, Inc.(NASDAQ:SQNM) stock jumped 7.55% to $3.99 after SQNM’s stock was upgraded by Jefferies Group from a “hold” rating to a “buy” rating in a research note issued this week. The firm currently has a $7.00 price target on the stock.

Additionally, the company announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

How Should Investors React To SQNM Now? Find Out Here

Idenix Pharmaceuticals, Inc.(NASDAQ:IDIX) shares climbed 7.31% and closed at $4.99. The company posted third quarter total revenues of $32.3 million, as compared to $2.6 million in the third quarter of 2011. The Company reported a net income of $4.3 million, or $0.03 per basic and diluted share, for the third quarter ended September 30, 2012, compared to a net loss of $11.7 million, or $0.12 per basic and diluted share for the third quarter ended September 30, 2011.

The company’s stock was downgraded by equities research analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Nov. 12. They currently have a $5.00 price target on the stock, down from their previous price target of $11.00.

How Should Investors React To IDIX Now? Find Out Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.




Related Press realease: